Sandoz rituximab (GP2013; SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL): Interim safety results of the non-interventional, observational, multicenter, open-label REFLECT study.

Manfred Welslau,Norbert Marschner,Thomas Wolff,Burkhard Otremba,Julian Topaly,Larissa Bittencourt da Silva

Sandoz rituximab (GP2013; SDZ-RTX) for the treatment of diffuse large B-cell lymphoma (DLBCL): Interim safety results of the non-interventional, observational, multicenter, open-label REFLECT study.

2019

Manfred Welslau
Norbert Marschner
Thomas Wolff
Burkhard Otremba
Julian Topaly
Larissa Bittencourt da Silva

e19020Background: SDZ-RTX is approved in Europe for the same indications as reference rituximab, based on the totality of evidence for biosimilarity. REFLECT, a real-world study of SDZ-RTX as curat...

Keywords:

Rituximab
Oncology
Pathology
Medicine
Diffuse large B-cell lymphoma
Internal medicine
Interim
Observational study
non interventional
open label

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations